Sensyne Health and OMNY Health have announced a strategic partnership focused on supporting artificial intelligence (AI) research.

Under this collaboration, Sensyne can contract for access to OMNY’s platform of over 22 million de-identified patient records across all therapeutics areas, in support of Sensyne’s data analytics work for life sciences companies.

Sensyne and OMNY have also agreed to work together on commercial projects for life sciences clients to advance ethical medical research. This will give both companies more opportunities to support important life sciences research, as biopharma clients will receive a joint offering of OMNY real-world data and Sensyne machine learning expertise.

The OMNY data network complements Sensyne’s existing global medical research data set of 22.1 million patients.

Derek Baird, president, North America, Sensyne Health said: “This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure and responsible way.”

Mitesh Rao, MD, CEO of OMNY Health, added: “OMNY Health embraces the opportunity to work with Sensyne Health’s world-class machine learning team and data science professionals, and is thrilled for Sensyne to join the platform. We aim to revolutionise the healthcare ecosystem through our equality-driven data network while unlocking transformative real world data partnerships across the life sciences industry.

“This collaboration with Sensyne Health creates even greater possibilities to apply emerging technologies to the unparalleled data we’ve assembled, enabling both companies to ethically innovate on behalf of our respective partners, and most importantly, to create better outcomes for patients.”

UK-based biotech company Silence Therapeutics has penned a collaboration with Hansoh Pharma to develop novel short interfering ribonucleic acid (siRNA) therapeutics for three undisclosed targets.

Under the terms of the deal, Hansoh will gain an exclusive option to license rights to the first two targets in Greater China, Hong Kong, Macau and Taiwan following the completion of Phase I trials.

Meanwhile, Silence will retain exclusive rights for those two targets in all other territories and will be responsible for all activities up to option exercise, and also retain responsibility outside the China region for post-Phase I studies.

In addition, Hansoh will have the exclusive option to license global rights to a third target at the point of IND filing, and will be responsible for all development activities post-option exercise for the third target.

In return, Hansoh will make a $16m upfront payment, with Silence also to be eligible to receive up to $1.3bn in additional development, regulatory and commercial milestones, plus tiered royalties from low double-digit to mid-teens on Hansoh net product sales.

“We believe Hansoh’s extensive clinical development and commercialisation experience in China make them an ideal partner. This collaboration is a good example of our hybrid model in action, balancing proprietary and partnered programmes to maximise the substantial opportunity of our mRNAi GOLD platform for targeting disease associated genes in the liver,” said Mark Rothera, president and chief executive officer of Silence Therapeutics.